Authors:
LONGINI IM
SAGATELIAN K
RIDA WN
HALLORAN ME
Citation: Im. Longini et al., OPTIMAL VACCINE TRIAL DESIGN WHEN ESTIMATING VACCINE EFFICACY FOR SUSCEPTIBILITY AND INFECTIOUSNESS FROM MULTIPLE POPULATIONS, Statistics in medicine, 17(10), 1998, pp. 1121-1136
Citation: Do. Dixon et al., HIV VACCINE TRIALS - SOME DESIGN ISSUES INCLUDING SAMPLE-SIZE CALCULATION, Journal of acquired immune deficiency syndromes, 6(5), 1993, pp. 485-496
Authors:
LAWRENCE DN
RIDA WN
SHEON A
FISCHER RD
HOFF R
Citation: Dn. Lawrence et al., HELD IN CONJUNCTION WITH THE CONFERENCE ON ADVANCES IN AIDS VACCINE DEVELOPMENT 5TH ANNUAL-MEETING, NATIONAL COOPERATIVE VACCINE DEVELOPMENT GROUPS ON AIDS (CHANTILLY, VIRGINIA, AUGUST 30-SEPTEMBER 2, 1992), AIDS research and human retroviruses, 9, 1993, pp. 190000125-190000126
Authors:
VERMUND SH
FISCHER RD
HOFF R
RIDA WN
SHEON AR
LAWRENCE DN
HOTH DF
BARKER LF
Citation: Sh. Vermund et al., PREPARING FOR HIV VACCINE EFFICACY TRIALS - PARTNERSHIPS AND CHALLENGES, AIDS research and human retroviruses, 9, 1993, pp. 190000127-190000132